Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH SLOW-RELEASE SODIUM-FLUORIDE
Autore:
PAK CYC; SAKHAEE K; ADAMSHUET B; PIZIAK V; PETERSON RD; POINDEXTER JR;
Indirizzi:
UNIV TEXAS,SW MED CTR DALLAS,CTR MINERAL METAB & CLIN RES,5323 HARRY HINES BLVD DALLAS TX 75235 SCOTT & WHITE MEM HOSP & CLIN TEMPLE TX 76508
Titolo Testata:
Annals of internal medicine
fascicolo: 6, volume: 123, anno: 1995,
pagine: 401 - 408
SICI:
0003-4819(1995)123:6<401:TOPOWS>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
CALCIUM CITRATE; REFLECTION ULTRASOUND; BONE; FRACTURE; QUALITY;
Keywords:
OSTEOPOROSIS, POSTMENOPAUSAL; SODIUM FLUORIDE; FRACTURES; DELAYED-ACTION PREPARATIONS; CALCIUM COMPOUNDS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
22
Recensione:
Indirizzi per estratti:
Citazione:
C.Y.C. Pak et al., "TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH SLOW-RELEASE SODIUM-FLUORIDE", Annals of internal medicine, 123(6), 1995, pp. 401-408

Abstract

Objective: To test whether slow-release sodium fluoride inhibits spinal fractures and is safe to use. Design: Placebo-controlled randomizedtrial. Interventions: Slow-release sodium fluoride, 25 mg twice daily, in four 14-month cycles (12 months receiving sodium fluoride followed by 2 months not receiving it) compared with placebo. Calcium citrate, 400 mg calcium twice daily, continuously in both groups. Patients: 48 of 54 patients who received sodium fluoride and 51 of 56 patients who received placebo completed at least 1 year of the study. All patients had postmenopausal osteoporosis. Results: Compared with the placebo group, the fluoride group had a lower individual vertebral fracture rate (0.064 +/- 0.182 per patient-year compared with 0.205 +/- 0.297 perpatient-year; P = 0.002), a higher unadjusted fracture-free rate (85.4% compared with 56.9%; P = 0.001), and a greater survival estimate (relative risk, 0.3 [95% CI, 0.12 to 0.76]) for new fractures; The recurrent spinal fracture rate did not differ between the two groups. The fluoride group had a substantial increase in L2-L4 bone mass of 4% to 5% per year for 4 years, a mean increase in femoral neck bone density of 2.38% +/- 3.33% pet year, and no change in radial shaft bone density. The frequency with which minor side effects and appendicular fractures occurred was similar in the two groups; no patients developed microfractures or gastric ulcers. Conclusion: Slow-release sodium fluoride and calcium citrate administered for 4 years inhibits new vertebral fractures (but not recurrent fractures), augments spinal and femoral neck bone mass, and is safe to use.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/05/20 alle ore 23:23:16